Monte Rosa Therapeutics vs Sutro Biopharma
GLUE and STRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GLUE and STRO compare
Monte Rosa Therapeutics is the larger company, worth 5.2 times as much as Sutro Biopharma ($880M against $170M).
Sutro Biopharma grew revenue faster over the last twelve months (−56.3% versus −61.3% for Monte Rosa Therapeutics).
Monte Rosa Therapeutics keeps more of each dollar of sales as profit, with a net margin of −186% compared with −395% at Sutro Biopharma.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GLUE | STRO |
|---|---|---|
| Size and price | ||
| Market cap | $880M | $170M |
| Share price | $10.31 | $10.26 |
| Change, 1 year | −26.7% | 27.3% |
| Change, 5 years | −47.3% | −94.2% |
| Beta (5Y) | 1.85 | 2.21 |
| Employees | 150 | 137 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 12.5× | 3.7× (better) |
| P/B | 1.8× | – |
| FCF yield | −19.8% | – |
| Fair value | $8.68 | – |
| Margin of safety | −18.8% | – |
| Growth | ||
| Revenue growth (TTM) | −61.3% | −56.3% (better) |
| Revenue growth, 5Y average | – | 19.1% |
| Net income growth (TTM) | −725% | – |
| EPS growth (TTM) | −660% | – |
| Profitability | ||
| Operating margin | −214% (better) | −320% |
| Net margin | −186% (better) | −395% |
| FCF margin | −248% | – |
| Return on equity | −35.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 10.32 (better) | 3.32 |
| Altman Z-score | 1.87 (better) | −8.74 |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 109% | 99.4% |
| Held by insiders | 11.5% | 6.1% |
| Insider net buying, 12 months | −$4.1M | $0 (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 27.6% | 14.5% |
Go deeper
- GLUE stock overview
- GLUE income statement
- GLUE valuation and score
- STRO stock overview
- STRO income statement
- STRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.